摘要
目的 观察贝伐单抗联合TP方案治疗铂类化疗复发卵巢癌的临床疗效及安全性.方法 选择34例敏感型复发性卵巢癌患者作为研究对象,所有患者均给予贝伐单抗联合紫杉醇和顺铂治疗.观察近期疗效、总生存期(OS)、无进展生存期(PFS)和化疗期间的不良反应发生率.结果 CR、PR、SD、PD患者分别为3例、24例、5例和2例,RR率为79.41%.中位PFS为12.7个月,中位0S为26.2个月.白细胞减少、血小板减少、中性粒细胞减少、胃肠道反应、转氨酶升高、高血压、鼻出血、蛋白尿、周围神经病变、黏膜炎发生率分别为73.53%、20.59%、67.65%、82.35%、47.06%、14.71%、5.88%、17.65%、29.41%和17.65%.结论 贝伐单抗联合TP方案治疗铂类敏感型复发性卵巢癌可较好的缓解病情,改善患者的生存时间,不良反应可控,安全性较好,具有临床推广价值.
Abstract
Objective To study the clinical efficacy and safety of bevacizumab combined with TP chemotherapy in platinum recurrent ovarian cancer.Methods34 patients with platinum sensitive recurrent ovarian cancer were seleted as the objects.All patients were treated with bevacizumab plus paclitaxel and cisplatin.The short-term effects, overall survival(OS), progression free survival(PFS) and incidence of adverse reaction during chemotherapy were observed.ResultsThe patients with CR, PR, SD and PD were 3 cases, 24 cases, 5 cases and 2 cases, respectively.The median PFS and median OS of patiens were 12.7months and 26.2 months, respectively.The incidence of decrease in leukocytes, thrombocytopenia, neutrophils, gastrointestinal reactions, elevated levels of transaminase, hypertension, epistaxis, proteinuria, peripheral neuropathy, mucositis were 73.53%, 20.59%, 67.65%, 82.35%, 47.06%, 14.71%, 5.88%, 17.65%, 29.41% and 17.65%, respectively.ConclusionThe bevacizumab combined with TP chemotherapy in treatment of platinum sensitive recurrent ovarian cancer can better relieve the disease, improve the survival time of the patient, the adverse reaction is controllable, and the safety is good, which has the clinical popularization value.
NETL
NSTL
维普
万方数据